Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2010

Lee Chun-Nin, Chen Hsiang-Yin, Liu H Eugene

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to ErbB Receptors
Share to Erlotinib Hydrochloride
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinazolines

Share to ras Proteins

Source

Identifiers

PMID: 20008635
DOI: 10.1200/JCO.2009.24.0747

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.PMID 20008635Read ↗

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.Semantic proximity Read ↗

Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.Semantic proximity Read ↗

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.Semantic proximity Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.Semantic proximity Read ↗

Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.Semantic proximity Read ↗

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.Semantic proximity Read ↗

Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.Semantic proximity Read ↗

A lung adenocarcinoma with rare epidermal growth factor receptor exon 20 V774M mutation was sensitive to osimertinib: A case report and molecular structural analysis.Semantic proximity Read ↗

Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.Semantic proximity Read ↗

EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.Semantic proximity Read ↗

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.